Zimbabwe has turned down a substantial American health deal worth 367 million US dollars (£272m) over five years over Washington's request for sensitive data.
The decision became public following a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
An official representative has since explained that the United States was seeking biological samples for scientific study and profit while refused to guarantee the resulting advantages from any future treatments.
"We are forced to start the difficult and regrettable process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged more negotiations to reach a deal agreeable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Implications
This rejection comes after a comparable situation in Kenya, where a high court suspended a similar deal with the US after concerns were filed about the security of citizens' health data.
Since returning to office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to enhance openness and accountability.
Based on statements, Sixteen nations in Africa have to date agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently on antiretroviral therapy through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, without any corresponding guarantee of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Put simply, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be accessible to our citizens should a new disease outbreak emerge."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining systems previously set up via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This system is intended to ensure that when a country contributes its data, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our US partners on how subsequent co-operation could be designed in a manner that honours the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts said it recognised the government's concerns, but suggested that talks must proceed considering a large portion of the country's HIV programmes relied on external financing.
"If specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," the group added.
The halted deal highlights the ongoing tensions between receiving vital international aid and protecting local interests in an ever more data-driven world.